What side effects are reported with Retatrutide?

Retatrutide is a once-weekly injectable medication developed by Eli Lilly that has shown promise in the treatment of obesity and type 2 diabetes. It works on 3 receptors that are involved in glucose metabolism and appetite regulation: glucagon-like peptide-1 (GLP-1) receptor, glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. The common side effects reported are similar to GLP-1 agonists, and include nausea, vomiting, diarrhea, abdominal discomfort, bloating, and constipation. There were reports that some people experienced a slight increase in their heart rate, which has also been seen with GLP-1 agonists. However, because of its unique mechanism of action, further research is needed to see what other side effects are possible.